Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13458098 | 0.81 | ALDH1A1 (0.33) | ALDH1A1KDM4EGLA | |
| SCHEMBL1200250 | 0.78 | KDM4E (0.53) | ALDH1A1KDM4EGLAGPR35RAB9A | |
| SCHEMBL9124172 | 0.74 | GPR35 (0.45) | ALDH1A1KDM4EGPR35RAB9ATSHR | |
| SCHEMBL3214901 | 0.70 | ALDH1A1 (0.49) | ALDH1A1KDM4EGLATSHRGRIN2D | |
| SCHEMBL9860083 | 0.70 | TDP1 (0.59) | ALDH1A1GPR35TSHRCYP1A2CYP3A4 | |
| SCHEMBL173688 | 0.69 | KDM4E (0.61) | ALDH1A1KDM4EGLAGPR35RAB9A | |
| SCHEMBL458846 | 0.69 | KDM4E (0.61) | ALDH1A1KDM4EGLAGPR35RAB9A | |
| SCHEMBL29071029 | 0.68 | DNA2 (0.37) | ALDH1A1KDM4EGLAGPR35RAB9A | |
| SCHEMBL30449050 | 0.68 | DNA2 (0.37) | ALDH1A1KDM4EGLAGPR35RAB9A | |
| SCHEMBL28825088 | 0.67 | GPR35 (0.52) | ALDH1A1GPR35TSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056535-A1 | Inhibitors of HIV-1 reverse transcriptase | ROCHE PALO ALTO LLC | 2010-03-04 | — | — | US | disclosed |
| EP-1670466-A4 | PREPARATION OF 1, 6, 7- TRISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| US-20070004771-A1 | Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED | 2007-01-04 | — | — | US | disclosed |
| EP-1670466-A2 | PREPARATION OF 1, 6, 7- TRISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005034866-A2 | PREPARATION OF 1, 6, 7- TRISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056535-A1 | Inhibitors of HIV-1 reverse transcriptase | QTRT1, NQO2, QTRT2 | ALDH1A1 301/4885KDM4E 750/4885GLA 1551/4885 |
| US-20070004771-A1 | Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors | ROCK1, TNK2, ARHGDIB | ALDH1A1 4385/4885KDM4E 969/4885GLA 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.